Deep characterization of the anti-drug antibodies developed in Fabry disease patients, a prospective analysis from the French multicenter cohort FFABRY
Wladimir Mauhin(Sorbonne Université), Olivier Benvéniste(Inserm), Damien Amelin(Inserm), K.H. Ly(Centre Hospitalier Universitaire de Limoges), Thierry Zénone(Centre Hospitalier de Valence), É. Hachulla(Centre Hospitalier Universitaire de Lille), Marie Matignon(Inserm), Bertrand Dussol(Aix-Marseille Université), Marjolaine Willems(Université de Montpellier), Olivier Lidove(Groupe Hospitalier Diaconesses Croix Saint-Simon), V. Leguy‐Seguin(CHU Dijon Bourgogne), Roseline Froissart(Hospices Civils de Lyon), Gaëlle Dzangué-Tchoupou(Inserm), Christian Lavigne(Université d'Angers), Louiza Arouche-Delaperche(Inserm), F. Maillot(Université de Tours), Didier Lacombe(Centre Hospitalier Universitaire de Bordeaux), Fabien Labombarda(Université de Caen Normandie), Gérard Besson(Centre Hospitalier Universitaire de Grenoble), A. Masseau(Centre Hospitalier Universitaire de Nantes), Federico Mingozzi(Spark Therapeutics (United States)), Foudil Lamari(Sorbonne Université), Claire Douillard(Centre Hospitalier Universitaire de Lille), Jean Marc Ziza, Catherine Caillaud(Hôpital Necker-Enfants Malades), Esther Noël(Hôpitaux Universitaires de Strasbourg), Pauline D’Halluin(Université de Tours)
Cited by 33
Related Papers
Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome
|New England Journal of Medicine|2009|857
Mapping and predicting mortality from systemic sclerosis
|Annals of the Rheumatic Diseases|2017|699
Mutations in genes encoding ribonuclease H2 subunits cause Aicardi-Goutières syndrome and mimic congenital viral brain infection
|Nature Genetics|2006|673
Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group
|Annals of the Rheumatic Diseases|2014|432